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n  83-year-old  Caucasian  male  presented  in  the  emergency
oom  with  active  lower  gastrointestinal  bleeding  with  few
ours  of  evolution  and  diffuse  abdominal  pain  with  3  days
f  duration.  The  patient  mentioned  signiﬁcant  weight  loss
uring  the  previous  year  (20  kg).  He  denied  previous  or
oncomitant  gastrointestinal  symptoms.  At  admission  he
as  hemodynamically  stable.  Laboratory  ﬁndings  showed
emoglobin  level  of  12.1  g/L,  without  other  abnormalities.
bdominal  examination  was  unremarkable  and  rectal  dig-
tal  examination  showed  bright  red  blood  on  the  ﬁnger
love.
A  left  colonoscopy  was  performed  and  revealed  loss  of
ormal  vascular  pattern,  descending  colon  with  granular
ucosa  and  some  ulcers  (Fig.  1),  sigmoid  colon  and  rec-
um  presented  multiple  bulky  polypoid  masses  protruding  to
he  lumen,  with  superﬁcial  erosions  and  bleeding  (Fig.  2).
iopsies  were  acquired  for  histological  evaluation.
An  abdominal  CT-scan  was  performed  and  revealed
eterogeneous  splenomegaly  and  multiple  mesenteric,
ara-aortic  and  intercavo-aortic  adenopathies.
Histological  examination  disclosed  atypical  lymphoid
ells  with  irregular  nuclei  without  conspicuous  nucleoli  and
cant  cytoplasm,  some  mitotic  ﬁgures  and  apoptotic  bodies
Fig.  3A).  Immunohistochemical  analysis:  positive  staining
or  CD20  (Fig.  3B)  and  CD5  (Fig.  3C).
Bone  marrow  involvement  was  also  conﬁrmed.  The  diag-
osis  of  mantle  cell  lymphoma  (MCL)  was  established  (stage
V).
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ttp://dx.doi.org/10.1016/j.jpg.2013.03.004The  patient  died  some  weeks  later  with  an  infectious
omplication  before  chemotherapy  was  initiated.
MCL  is  an  aggressive  B  cell  neoplasm  of  small  to  medium
ized  lymphocytes  with  over  expression  of  cyclin  D1  caused
y  translocation  (11;14).  Immunophenotyping  is  commonly
sed,  the  majority  of  MCL  co-express  CD20,  CD5  and  cyclin
1  and  are  usually  negative  for  CD10  and  Bcl6.1,2
MCL  represents  about  4%  of  all  lymphomas  in  the  US  and
--9%  in  Europe.1 MCL  arises  in  older  adults  (median  age  of
resentation  60--65  years)  and  has  a  male  predominance.1--3
The  presence  of  multiple  lymphomatous  polyps  along  the
astrointestinal  (GI)  tract  was  ﬁrst  described  in  1961  as  clin-
copathological  entity,  ‘‘Multiple  Lymphomatous  Polyposis’’
MLP),  and  subsequently  was  found  to  represent  involvement
f  the  GI  tract  by  MCL.  Whether  MLP  as  GI  tract  MCL  is  a  dif-
erent  entity  from  the  involvement  of  GI  tract  in  peripheral
CL  is  not  clear.4
The  reported  frequency  of  GI  tract  involvement  in
atients  with  MCL  is  probably  underestimated  because,  in
ost  studies,  endoscopic  evaluation  was  only  performed  in
atients  with  GI  symptoms.  A  study  that  aimed  to  determine
he  frequency  of  GI  involvement  and  its  clinical  signiﬁcance
n  MCL  found  that  only  26%  of  patients  presented  with  GI
ymptoms  at  the  time  of  diagnosis.  In  the  same  study,  MCL
as  present  histologically  in  the  lower  GI  tract  of  53  of
0  patients  (88%)  and  in  the  upper  GI  tract  of  28  of  58
atients  (43%).  Microscopic  evidence  of  disease  was  found
n  a  signiﬁcant  number  of  patients  with  macroscopically
ormal  endoscopic  evaluation.5 Colonoscopy  and  upper  GI
ndoscopy,  as  part  of  staging  investigations  in  MCL,  rarely
hanges  clinical  management,  therefore,  routine  endoscopy
nd  colonoscopy  cannot  be  recommended  for  all  patients  at
aseline.3,5
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Figure  1  Descending  colon  with  loss  of  normal  vessel  pattern,
edematous  mucosa  and  ulceration.
Figure  2  Sigmoid  colon  with  polypoid  masses  protruding  to
the lumen.
Figure  3  Histological  features:  (A)  hematoxylin  and  eosin  staining  400×; (B)  staining  for  CD20;  (C)  staining  for  CD5.
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Patients  with  MCL  generally  have  stage  III/IV  disease  at
resentation  and  despite  treatment  the  overall  prognosis
emains  poor.1,2
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